2Alvarez F, Berg PA, Bianchi FB,et al. International antoimmune hepatitis group report: review of criteria for diangnosis of autoimmune hepatitis. J Hepatol, 1999 ;31:929.
3Heathcote EJ. Managemont of primary biliary cirrhosis, the American association for the study of liver diseases : practice guidelines. J Hepatol, 2000 ;31 : 1005.
4Alvarez F, Berg PA, Bianchi FB, et al. International Antoimmunc Hepatitis Group Report:review of criteria for diangnosis of auto- immune hepatitis[J]. J Hepatol, 1999, 31(5) :929-938.
5Heathcote EJ. Managemont of primary biliary cirrhosis, the A- merican association for the study of liver diseases: practice guide- lines[J]. Hepatology, 2000,31 (4) : 1005-1013.
7Panmgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited [J]. Hepatology, 2002 Sep; 36(3), 525-531.
8Li X Q, Andersson T B, Ahlstr?m M, et al.Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomepra- zole, lansoprazole, pantoprazole, and rabeprazole on human cytoc- hrome P450 activities[J]. Drug Metab Dispos, 2004,32(8):821-827.
9Shneider B L.Progressive intrahepatic cholestasis: mechanisms, diagnosis and theraov[J]..Pediatr Transtplant. 2004,8(6):609-612.
10Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines[J]. Hepatology, 2000, 31 (4) : 1005- 1013.
